IL315266A - Anti-coagulation factor xi antibodies - Google Patents
Anti-coagulation factor xi antibodiesInfo
- Publication number
- IL315266A IL315266A IL315266A IL31526624A IL315266A IL 315266 A IL315266 A IL 315266A IL 315266 A IL315266 A IL 315266A IL 31526624 A IL31526624 A IL 31526624A IL 315266 A IL315266 A IL 315266A
- Authority
- IL
- Israel
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence shown
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349888P | 2016-06-14 | 2016-06-14 | |
| PCT/US2017/036940 WO2017218371A1 (en) | 2016-06-14 | 2017-06-12 | Anti-coagulation factor xi antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315266A true IL315266A (en) | 2024-10-01 |
Family
ID=59078269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315266A IL315266A (en) | 2016-06-14 | 2017-06-12 | Anti-coagulation factor xi antibodies |
| IL263272A IL263272B2 (en) | 2016-06-14 | 2017-06-12 | Antibodies to coagulation factor xi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL263272A IL263272B2 (en) | 2016-06-14 | 2017-06-12 | Antibodies to coagulation factor xi |
Country Status (29)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| WO2017218371A1 (en) * | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| US11168147B2 (en) | 2016-12-23 | 2021-11-09 | Novartis Ag | Factor XI antibodies and methods of use |
| CN110423278B (zh) | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| KR20230034361A (ko) * | 2020-07-02 | 2023-03-09 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도 |
| EP4177275A4 (en) * | 2020-07-03 | 2024-07-17 | Suzhou Alphamab Co., Ltd | COAGULATION FACTOR XI (FXI)-BINDING PROTEIN |
| WO2022171656A1 (en) * | 2021-02-09 | 2022-08-18 | Arxx Therapeutics As | Anti-s100a4 humanized antibodies, uses and methods |
| WO2023098637A1 (zh) * | 2021-11-30 | 2023-06-08 | 苏州康宁杰瑞生物科技有限公司 | 预防和/或治疗血栓栓塞性疾病的方法 |
| WO2024141099A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
| WO2025130748A1 (zh) * | 2023-12-22 | 2025-06-26 | 四川科伦博泰生物医药股份有限公司 | 一种抗凝血因子XI/XIa抗体制剂 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| EP0420937B1 (en) | 1988-06-21 | 1994-11-09 | Genentech, Inc. | Therapeutic compositions for the treatment of myocardial infarction |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH0656382A (ja) | 1992-08-04 | 1994-03-01 | Kawasaki Steel Corp | コークス乾式消火装置のバケット巻上機の吊ビーム装置 |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| KR100483494B1 (ko) | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
| AU778392B2 (en) | 2000-03-03 | 2004-12-02 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin and their use |
| CA2492671C (en) | 2002-03-22 | 2012-04-17 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| TWI382031B (zh) | 2003-07-15 | 2013-01-11 | Amgen Inc | 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體 |
| AR051805A1 (es) | 2004-12-21 | 2007-02-07 | Centocor Inc | Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007067992A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
| WO2007067730A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
| KR20090024745A (ko) | 2006-06-06 | 2009-03-09 | 크루셀 홀란드 비.브이. | 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 |
| TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| US8598321B2 (en) | 2007-03-22 | 2013-12-03 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| AU2008303796B2 (en) | 2007-09-26 | 2014-09-18 | Amgen Inc. | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| AU2016203944A1 (en) | 2007-11-21 | 2016-07-07 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| DK3002298T3 (da) | 2007-11-21 | 2019-10-28 | Univ Oregon Health & Science | Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| HRP20181727T1 (hr) * | 2008-06-19 | 2019-02-08 | Prothix Bv | Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška |
| EP2313434A4 (en) | 2008-07-31 | 2013-03-27 | Univ California | ANTIBODIES FOR NEUTRALIZING BOTULINE NEUROTOXINES |
| SI2350304T1 (sl) | 2008-10-31 | 2017-04-26 | Janssen Biotech, Inc. | Antagonisti toll-u podobnega receptorja |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| CA2747519C (en) | 2008-12-18 | 2019-04-02 | Oregon Health & Science University | Anti-fxi antibodies and methods of use |
| CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| CA2758964A1 (en) | 2009-04-16 | 2010-10-21 | Abbott Biotherapeutics Corp. | Anti-tnf-.alpha. antibodies and their uses |
| EP2949673A1 (en) | 2009-04-27 | 2015-12-02 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
| EP2488553B1 (en) | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Cancer treatment |
| EP2496600A1 (en) | 2009-11-04 | 2012-09-12 | Fabrus LLC | Methods for affinity maturation-based antibody optimization |
| ES2776980T3 (es) | 2009-12-23 | 2020-08-03 | Merck Sharp & Dohme | Línea celular 3M |
| JP2013519164A (ja) * | 2010-02-03 | 2013-05-23 | トリロジー アイピー ホールディングス，インコーポレイテッド | モバイル通信プラン提供 |
| AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
| CA2815154A1 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
| CN103874707B (zh) | 2010-11-19 | 2017-04-19 | 卫材R&D管理有限公司 | 中和抗‑ccl20抗体 |
| CN105713092B (zh) | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| EP2694553B1 (en) | 2011-04-01 | 2017-10-11 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
| JP6141834B2 (ja) | 2011-06-06 | 2017-06-07 | ノヴォ ノルディスク アー／エス | 治療抗体 |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| DK2650310T3 (en) | 2012-04-13 | 2016-09-12 | Rottapharm Biotech Srl | The anti-ADAMTS-5 antibody, derivatives and uses thereof |
| HUE040580T2 (hu) * | 2012-05-10 | 2019-03-28 | Bayer Pharma AG | XI. véralvadási faktorhoz és/vagy XIA aktivált alakjához kötõdni képes ellenanyagok és alkalmazásuk |
| US9944707B2 (en) | 2012-05-17 | 2018-04-17 | Sorrento Therapeutics, Inc. | Antibodies that bind epidermal growth factor receptor (EGFR) |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| CN106232625B (zh) | 2013-10-01 | 2020-04-24 | 免疫医疗有限公司 | 治疗和诊断过表达α-V-β-6的癌症的方法 |
| BR112016021576A2 (pt) | 2014-03-20 | 2017-10-10 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento? |
| MX355107B (es) | 2014-06-03 | 2018-04-04 | Xbiotech Inc | Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus. |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| PT3280441T (pt) | 2015-04-07 | 2021-11-30 | Alector Llc | Anticorpos anti-sortilina e métodos para a sua utilização |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| WO2017015619A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| WO2017058944A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors |
| MA43660A (fr) | 2016-01-22 | 2018-11-28 | Adimab Llc | Anticorps anti-facteur xi de coagulation |
| WO2017218371A1 (en) | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| BR112019005449A2 (pt) | 2016-09-20 | 2019-10-01 | Aronora Inc | anticorpos inovadores contra fator xi e usos dos mesmos |
-
2017
- 2017-06-12 WO PCT/US2017/036940 patent/WO2017218371A1/en not_active Ceased
- 2017-06-12 KR KR1020197001266A patent/KR102218714B1/ko active Active
- 2017-06-12 TN TNP/2018/000417A patent/TN2018000417A1/en unknown
- 2017-06-12 TW TW106119391A patent/TWI752964B/zh active
- 2017-06-12 BR BR112018075858-2A patent/BR112018075858A2/pt unknown
- 2017-06-12 CA CA3025869A patent/CA3025869C/en active Active
- 2017-06-12 CA CA3172367A patent/CA3172367A1/en active Pending
- 2017-06-12 JP JP2018565042A patent/JP7022081B2/ja active Active
- 2017-06-12 KR KR1020217004608A patent/KR102379580B1/ko active Active
- 2017-06-12 GE GEAP201714983A patent/GEP20227382B/en unknown
- 2017-06-12 SG SG11201810763TA patent/SG11201810763TA/en unknown
- 2017-06-12 TW TW110149482A patent/TWI802193B/zh active
- 2017-06-12 IL IL315266A patent/IL315266A/en unknown
- 2017-06-12 AU AU2017286432A patent/AU2017286432B2/en active Active
- 2017-06-12 MX MX2018015757A patent/MX2018015757A/es unknown
- 2017-06-12 CN CN202310501882.9A patent/CN116425879A/zh active Pending
- 2017-06-12 SG SG10202103120UA patent/SG10202103120UA/en unknown
- 2017-06-12 PE PE2018003203A patent/PE20190416A1/es unknown
- 2017-06-12 AR ARP170101603A patent/AR108717A1/es unknown
- 2017-06-12 UA UAA201900311A patent/UA129793C2/uk unknown
- 2017-06-12 US US15/619,620 patent/US10676536B2/en active Active
- 2017-06-12 MA MA045234A patent/MA45234A/fr unknown
- 2017-06-12 CN CN201780037421.3A patent/CN109476758B/zh active Active
- 2017-06-12 IL IL263272A patent/IL263272B2/en unknown
- 2017-06-12 EA EA201892716A patent/EA201892716A1/ru unknown
- 2017-06-12 CR CR20180583A patent/CR20180583A/es unknown
- 2017-06-12 EP EP17731444.0A patent/EP3469002A1/en active Pending
- 2017-06-12 MY MYPI2018002406A patent/MY201852A/en unknown
- 2017-06-16 JO JOP/2018/0121A patent/JOP20180121A1/ar unknown
-
2018
- 2018-12-06 PH PH12018502586A patent/PH12018502586A1/en unknown
- 2018-12-10 NI NI201800134A patent/NI201800134A/es unknown
- 2018-12-11 CL CL2018003565A patent/CL2018003565A1/es unknown
- 2018-12-11 EC ECSENADI201891593A patent/ECSP18091593A/es unknown
- 2018-12-12 CO CONC2018/0013434A patent/CO2018013434A2/es unknown
- 2018-12-13 DO DO2018000284A patent/DOP2018000284A/es unknown
- 2018-12-14 MX MX2023012740A patent/MX2023012740A/es unknown
-
2020
- 2020-05-01 US US16/864,577 patent/US11485794B2/en active Active
- 2020-05-01 US US16/864,570 patent/US11512142B2/en active Active
- 2020-05-01 US US16/864,583 patent/US11479615B2/en active Active
- 2020-05-01 US US16/864,559 patent/US11661460B2/en active Active
- 2020-07-30 AU AU2020210233A patent/AU2020210233B2/en active Active
-
2021
- 2021-03-26 JP JP2021053470A patent/JP7277500B2/ja active Active
-
2023
- 2023-04-18 US US18/302,033 patent/US12275800B2/en active Active
-
2024
- 2024-02-06 CL CL2024000367A patent/CL2024000367A1/es unknown
- 2024-02-20 AU AU2024201084A patent/AU2024201084A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315266A (en) | Anti-coagulation factor xi antibodies | |
| JP2021101720A5 (cg-RX-API-DMAC7.html) | ||
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| US11390676B2 (en) | Anti-LAG-3 antibodies and compositions | |
| TWI545133B (zh) | 抗－ｉｌ－２３抗體 | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2017052784A5 (cg-RX-API-DMAC7.html) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2013538057A5 (cg-RX-API-DMAC7.html) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2012504955A5 (cg-RX-API-DMAC7.html) | ||
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| RU2020133229A (ru) | Антитела к klk5 и способы применения | |
| JP2016513682A5 (cg-RX-API-DMAC7.html) | ||
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина |